SHANGHAI, May 20, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the supplemental application for MAIWEIJIAN (Denosumab Injection, R&D code: 9MW0321), which was independently...
Hence then, the article about mabwell announces nmpa approval of supplemental application for additional indications of maiweijian denosumab injection was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Mabwell Announces NMPA Approval of Supplemental Application for Additional Indications of MAIWEIJIAN (Denosumab Injection) )
Also on site :
- A dating expert says ghosting and quiet quitting are the same problem at their core, and corporate life has more to learn from romance than it admits
- Stephen Colbert’s 15 Funniest ‘Late Show’ Moments That Still Make Us Cry-Laugh
- Elon Musk’s SpaceX unveils filing for blockbuster IPO